No Data
SciSparc Ltd. Reports Changes in Financial Position
SciSparc | 6-K: Report of foreign private issuer (related to financial reporting)
SciSparc Ltd. Gains Shareholder Approval for Proposals
SciSparc Ltd. Reschedules Annual General Meeting
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
SciSparc Receives FDA Approval To Launch Pivotal Phase IIb Trial For Tourette Syndrome Treatment SCI-110 In U.S., Following Promising Phase IIa Results Showing Up To 40% Tic Reduction
No Data
No Data